What is EyePromise?
EyePromise is a prominent provider of scientifically validated eye vitamins designed to enhance both ocular and overall health. Their product portfolio caters to a broad audience, including individuals focused on age-related eye health, those experiencing occasional dry eye, and athletes seeking performance optimization through nutritional support. The company emphasizes its commitment to efficacy and quality, evidenced by its collaborations with eye care professionals and endorsements from professional athletes. This strategic positioning within the health and wellness market, particularly in specialized nutritional supplements for vision, highlights its unique value proposition.
How much funding has EyePromise raised?
EyePromise has raised a total of $3.4M across 2 funding rounds:
Private Equity
$3M
Debt
$350K
Private Equity (2014): $3M with participation from DSM Venturing
Debt (2020): $350K led by PPP
Key Investors in EyePromise
DSM Venturing
DSM Venturing is the venture capital arm of Royal DSM, a global science-based company focused on Nutrition, Health, and Sustainable Living. They typically invest in innovative companies that align with DSM's strategic interests in life sciences and materials.
PPP
Public-Private Partnership
What's next for EyePromise?
The recent major strategic investment suggests EyePromise is poised for significant expansion and further product development. This capital infusion will likely fuel initiatives aimed at broadening market reach, enhancing research and development for new formulations, and strengthening partnerships within the eye care industry. The company's focus on science-backed solutions and professional endorsement positions it for continued growth and leadership in the competitive eye health supplement market.
See full EyePromise company page
